Literature DB >> 30615119

Rapid Boosting of HIV-1 Neutralizing Antibody Responses in Humans Following a Prolonged Immunologic Rest Period.

Paul Spearman1, Georgia D Tomaras2, David C Montefiori2, Ying Huang3, Marnie L Elizaga3, Guido Ferrari2, S Munir Alam2, Abby Isaacs3, Hasan Ahmed4, John Hural3, M Juliana McElrath3, Laissa Ouedraogo5, Michael Pensiero5, Chris Butler5, Spyros A Kalams6, Edgar Turner Overton7, Susan W Barnett8.   

Abstract

BACKGROUND: The durability and breadth of human immunodeficiency virus type 1 (HIV-1)-specific immune responses elicited through vaccination are important considerations in the development of an effective HIV-1 vaccine. Responses to HIV-1 envelope subunit protein (Env) immunization in humans are often described as short-lived.
METHODS: We enrolled 16 healthy volunteers who had received priming with an HIV-1 subtype B Env vaccine given with MF59 adjuvant 5-17 years previously and 20 healthy unprimed volunteers. Three booster immunizations with a heterologous subtype C trimeric gp140 protein vaccine were administered to the primed group, and the same subtype C gp140 protein vaccination regimen was administered to the unprimed subjects.
RESULTS: Binding antibodies and neutralizing antibodies to tier 1 viral isolates were detected in the majority of previously primed subjects. Remarkably, a single dose of protein boosted binding and neutralizing antibody titers in 100% of primed subjects following this prolonged immunologic rest period, and CD4+ T-cell responses were boosted in 75% of primed individuals.
CONCLUSIONS: These results demonstrate that HIV-1 protein immunogens can elicit durable memory T- and B-cell responses and that strong tier 1 virus neutralizing responses can be elicited by a single booster dose of protein following a long immunologic rest period. However, we found no evidence that cross-clade boosting led to a significantly broadened neutralizing antibody response.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV envelope; HIV vaccine; neutralization breadth; neutralizing antibodies

Mesh:

Substances:

Year:  2019        PMID: 30615119      PMCID: PMC6775047          DOI: 10.1093/infdis/jiz008

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  44 in total

1.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Authors:  Yuxing Li; Stephen A Migueles; Brent Welcher; Krisha Svehla; Adhuna Phogat; Mark K Louder; Xueling Wu; George M Shaw; Mark Connors; Richard T Wyatt; John R Mascola
Journal:  Nat Med       Date:  2007-08-26       Impact factor: 53.440

2.  A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.

Authors:  S Nitayaphan; C Khamboonruang; N Sirisophana; P Morgan; J Chiu; A M Duliege; C Chuenchitra; T Supapongse; K Rungruengthanakit; M deSouza; J R Mascola; K Boggio; S Ratto-Kim; L E Markowitz; D Birx; V Suriyanon; J G McNeil; A E Brown; R A Michael
Journal:  Vaccine       Date:  2000-02-14       Impact factor: 3.641

3.  Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen.

Authors:  Heather E Lynch; Shelley M Stewart; Thomas B Kepler; Gregory D Sempowski; S Munir Alam
Journal:  J Immunol Methods       Date:  2013-12-04       Impact factor: 2.303

4.  Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.

Authors:  Thomas G Evans; Sharon Frey; Heidi Israel; Joseph Chiu; Raphaelle El-Habib; Peter Gilbert; Alicia Gaitan; David C Montefiori
Journal:  Vaccine       Date:  2004-06-30       Impact factor: 3.641

5.  Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia.

Authors:  Georgia D Tomaras; Nicole L Yates; Pinghuang Liu; Li Qin; Genevieve G Fouda; Leslie L Chavez; Allan C Decamp; Robert J Parks; Vicki C Ashley; Judith T Lucas; Myron Cohen; Joseph Eron; Charles B Hicks; Hua-Xin Liao; Steven G Self; Gary Landucci; Donald N Forthal; Kent J Weinhold; Brandon F Keele; Beatrice H Hahn; Michael L Greenberg; Lynn Morris; Salim S Abdool Karim; William A Blattner; David C Montefiori; George M Shaw; Alan S Perelson; Barton F Haynes
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

6.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Authors:  Rajesh P Ringe; Rogier W Sanders; Anila Yasmeen; Helen J Kim; Jeong Hyun Lee; Albert Cupo; Jacob Korzun; Ronald Derking; Thijs van Montfort; Jean-Philippe Julien; Ian A Wilson; Per Johan Klasse; Andrew B Ward; John P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-21       Impact factor: 11.205

7.  Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

Authors:  Iain Stephenson; Karl G Nicholson; Katja Hoschler; Maria C Zambon; Kathy Hancock; Joshua DeVos; Jacqueline M Katz; Michaela Praus; Angelika Banzhoff
Journal:  N Engl J Med       Date:  2008-10-09       Impact factor: 91.245

8.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226

9.  Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay.

Authors:  Justin Pollara; Chiara Orlandi; Charles Beck; R Whitney Edwards; Yi Hu; Shuying Liu; Shixia Wang; Richard A Koup; Thomas N Denny; Shan Lu; Georgia D Tomaras; Anthony DeVico; George K Lewis; Guido Ferrari
Journal:  Cytometry A       Date:  2018-03-02       Impact factor: 4.355

10.  Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.

Authors:  Ming Tian; Cheng Cheng; Xuejun Chen; Hongying Duan; Hwei-Ling Cheng; Mai Dao; Zizhang Sheng; Michael Kimble; Lingshu Wang; Sherry Lin; Stephen D Schmidt; Zhou Du; M Gordon Joyce; Yiwei Chen; Brandon J DeKosky; Yimin Chen; Erica Normandin; Elizabeth Cantor; Rita E Chen; Nicole A Doria-Rose; Yi Zhang; Wei Shi; Wing-Pui Kong; Misook Choe; Amy R Henry; Farida Laboune; Ivelin S Georgiev; Pei-Yi Huang; Suvi Jain; Andrew T McGuire; Eric Georgeson; Sergey Menis; Daniel C Douek; William R Schief; Leonidas Stamatatos; Peter D Kwong; Lawrence Shapiro; Barton F Haynes; John R Mascola; Frederick W Alt
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

View more
  4 in total

1.  Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.

Authors:  Zanele Ditse; Nonhlanhla N Mkhize; Michael Yin; Michael Keefer; David C Montefiori; Georgia D Tomaras; Gavin Churchyard; Kenneth H Mayer; Shelly Karuna; Cecilia Morgan; Linda-Gail Bekker; Koleka Mlisana; Glenda Gray; Zoe Moodie; Peter Gilbert; Penny L Moore; Carolyn Williamson; Lynn Morris
Journal:  mSphere       Date:  2020-01-29       Impact factor: 4.389

2.  Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates.

Authors:  Peng Xiao; Krista Dienger-Stambaugh; Xuemin Chen; Huiling Wei; Shannon Phan; Ashley C Beavis; Karnail Singh; Nihar R Deb Adhikary; Pooja Tiwari; Francois Villinger; Biao He; Paul Spearman
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

3.  Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans.

Authors:  Kelly E Seaton; Aaron Deal; Xue Han; Shuying S Li; Ashley Clayton; Jack Heptinstall; Ann Duerr; Mary A Allen; Xiaoying Shen; Sheetal Sawant; Nicole L Yates; Paul Spearman; Gavin Churchyard; Paul A Goepfert; Janine Maenza; Glenda Gray; Giuseppe Pantaleo; Laura Polakowski; Harriet L Robinson; Shannon Grant; April K Randhawa; Ying Huang; Cecilia Morgan; Nicole Grunenberg; Shelly Karuna; Peter B Gilbert; M Juliana McElrath; Yunda Huang; Georgia D Tomaras
Journal:  NPJ Vaccines       Date:  2021-04-15       Impact factor: 7.344

4.  AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.

Authors:  Yunda Huang; Kelly E Seaton; Martin Casapia; Laura Polakowski; Stephen C De Rosa; Kristen Cohen; Chenchen Yu; Marnie Elizaga; Carmen Paez; Maurine D Miner; Colleen F Kelley; Janine Maenza; Michael Keefer; Javier R Lama; Magdalena Sobieszczyk; Susan Buchbinder; Lindsey R Baden; Carter Lee; Vineeta Gulati; Faruk Sinangil; David Montefiori; M Juliana McElrath; Georgia D Tomaras; Harriet L Robinson; Paul Goepfert
Journal:  Vaccine       Date:  2021-07-03       Impact factor: 4.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.